EXEL
Exelixis Inc.
as 12-18-2024 10:36am EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
More About Our EXEL ML Model...
What kind of parameters do you use to train EXEL stocks ML model?
To train our stocks EXEL ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
How often do you update EXEL ML model?
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Why is the accuracy of your EXEL model low?
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
How can I provide and share more data with you to increase your ML model accuracy?
We would greatly appreciate your contribution. Please send an email to [email protected]
Do you offer an ML model for shorter time periods, such as 5 minutes or 15 minutes?
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Can I rely on your ML model to make financial decisions regarding buying or selling stocks, or is it only intended for learning purposes?
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Share on Social Networks:
Disclaimer
Our EXEL ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"EXEL Forecast & Prediction for December 18, 2024 Exelixis Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.